SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Xochelli Aliki) "

Search: WFRF:(Xochelli Aliki)

  • Result 1-10 of 35
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Baliakas, Panagiotis, 1977-, et al. (author)
  • Cytogenetic complexity in chronic lymphocytic leukemia : definitions, associations, and clinical impact
  • 2019
  • In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 133:11, s. 1205-1216
  • Journal article (peer-reviewed)abstract
    • Recent evidence suggests that complex karyotype (CK) defined by the presence of >= 3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with >= 5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage, TP53 aberrations (deletion of chromosome 17p and/or TP53 mutations [TP53abs]), and the expression of somatically hypermutated (M-CLL) or unmutated immunoglobulin heavy variable genes. Thus, they contrasted with CK cases with 3 or 4 aberrations (low-CK and intermediate-CK, respectively) who followed aggressive disease courses only in the presence of TP53abs. At the other end of the spectrum, patients with CK and 112,119 displayed an exceptionally indolent profile. Building upon CK, TP53abs, and immunoglobulin heavy variable gene somatic hyper-mutation status, we propose a novel hierarchical model in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with 112,119, show the longest overall survival. Thus, CK should not be axiomatically considered unfavorable in CLL, representing a heterogeneous group with variable clinical behavior. High-CK with >= 5 chromosomal aberrations emerges as prognostically adverse, independent of other biomarkers. Prospective clinical validation is warranted before ultimately incorporating high-CK in risk stratification of CLL.
  •  
6.
  •  
7.
  •  
8.
  • Baliakas, Panagiotis, 1977-, et al. (author)
  • Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
  • 2019
  • In: Haematologica. - : Ferrata Storti Foundation (Haematologica). - 1592-8721 .- 0390-6078. ; 104:2, s. 360-369
  • Journal article (peer-reviewed)abstract
    • Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q) and/or SF3B1 mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.
  •  
9.
  •  
10.
  • Bikos, Vasilis, et al. (author)
  • An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
  • 2016
  • In: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 22:8, s. 2032-2040
  • Journal article (peer-reviewed)abstract
    • Purpose: Prompted by the extensive biases in the immunoglobulin (IG) gene repertoire of splenic marginal-zone lymphoma (SMZL), supporting antigen selection in SMZL ontogeny, we sought to investigate whether antigen involvement is also relevant post-transformation. Experimental Design: We conducted a large-scale subcloning study of the IG rearrangements of 40 SMZL cases aimed at assessing intraclonal diversification (ID) due to ongoing somatic hypermutation (SHM). Results: ID was identified in 17 of 21 (81%) rearrangements using the immunoglobulin heavy variable (IGHV) 1-2*04 gene versus 8 of 19 (40%) rearrangements utilizing other IGHV genes (P = 0.001). ID was also evident in most analyzed IG light chain gene rearrangements, albeit was more limited compared with IG heavy chains. Identical sequence changes were shared by subclones from different patients utilizing the IGHV1-2*04 gene, confirming restricted ongoing SHM profiles. Non-IGHV1-2*04 cases displayed both a lower number of ongoing SHMs and a lack of shared mutations (per group of cases utilizing the same IGHV gene). Conclusions: These findings support ongoing antigen involvement in a sizable portion of SMZL and further argue that IGHV1-2*04 SMZL may represent a distinct molecular subtype of the disease.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 35
Type of publication
journal article (33)
conference paper (2)
Type of content
peer-reviewed (21)
other academic/artistic (14)
Author/Editor
Stamatopoulos, Kosta ... (34)
Xochelli, Aliki (34)
Anagnostopoulos, Ach ... (21)
Rosenquist, Richard (19)
Ghia, Paolo (19)
Hadzidimitriou, Anas ... (15)
show more...
Oscier, David (15)
Sutton, Lesley-Ann (14)
Pospisilova, Sarka (14)
Stalika, Evangelia (14)
Agathangelidis, Andr ... (13)
Baliakas, Panagiotis (12)
Davis, Zadie (12)
Belessi, Chrysoula (11)
Davi, Frederic (10)
Stavroyianni, Niki (10)
Papadaki, Theodora (8)
Campo, Elias (7)
Plevova, Karla (7)
Athanasiadou, Anasta ... (7)
Scarfo, Lydia (6)
Darzentas, Nikos (6)
Giudicelli, Veroniqu ... (6)
Lefranc, Marie-Paule (6)
Baliakas, Panagiotis ... (6)
Panagiotidis, Panagi ... (6)
Espinet, Blanca (6)
Navarro, Alba (6)
Karypidou, Maria (6)
Kanellis, George (6)
Mattsson, Mattias (5)
Boudjogra, Myriam (5)
Chatzouli, Maria (5)
Trentin, Livio (5)
Ponzoni, Maurilio (5)
Sundström, Christer (4)
Mansouri, Larry (4)
Langerak, Anton W. (4)
Chiorazzi, Nicholas (4)
Puiggros, Anna (4)
Minga, Eva (4)
Collado, Rosa (4)
Moysiadis, Theodoros (4)
Strefford, Jonathan ... (4)
Iskas, Michalis (4)
Catherwood, Mark (4)
Montillo, Marco (4)
Jelinek, Diane F. (4)
Tzovaras, Dimitrios (4)
Kavakiotis, Ioannis (4)
show less...
University
Uppsala University (35)
Karolinska Institutet (8)
Lund University (2)
Language
English (34)
Spanish (1)
Research subject (UKÄ/SCB)
Medical and Health Sciences (33)
Natural sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view